⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of RayzeBio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
RayzeBio
↗San Diego, USA
RayzeBio is a clinical-stage radiopharmaceutical therapeutics (RPT) company focused on developing targeted cancer therapies. The company utilizes actinium-225, an alpha-emitting isotope, to deliver targeted radiation to solid tumors, aiming to provide more effective and precise treatment options compared to existing therapies.
Following its acquisition by Bristol Myers Squibb in February 2024 for approximately $4.1 billion, RayzeBio operates as a wholly owned subsidiary. The company maintains a focus on its pipeline of RPT candidates, including its lead program RYZ101, and continues to develop its in-house manufacturing capabilities.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2020
Ownership:subsidiary
Status:acquired
FUNDING
Total Raised:$426M
Investors:Venrock
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Radiopharmaceutical
Active Trials:0
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Bristol Myers Squibb
Acquired By:Bristol Myers Squibb (2024-02-01)
Key Partnerships:Bristol Myers Squibb (Acquirer)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, C4 Therapeutics
LEADERSHIP
Key Executives:
Ken Song - CEO
Scientific Founders:Deborah Charych
LINKS
Website:rayzebio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with RayzeBio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.